Explore

Phase 3 Trial for mRNA Vaccine Targets H5N1 Influenza Preparedness

Phase 3 Trial for mRNA Vaccine Targets H5N1 Influenza Preparedness

A phase 3 clinical trial is underway to test the effectiveness of an mRNA vaccine for the H5N1 influenza strain, a virus primarily found in birds but potentially dangerous to humans. The trial aims to develop a vaccine that could be rapidly deployed in the event of a mutation leading to widespread human transmission. This initiative is part of a broader effort to enhance global preparedness for future pandemics, following the lessons learned from the COVID-19 pandemic. The trial is being closely watched by governments and health organizations worldwide, eager to improve their response capabilities to emerging infectious diseases.

Moderna Begins Trial of mRNA Vaccine for H5N1 Bird Flu in US and UK

Moderna Begins Trial of mRNA Vaccine for H5N1 Bird Flu in US and UK

Moderna has initiated a pivotal trial for its mRNA-based vaccine targeting the H5N1 bird flu strain, with the trial taking place in both the United States and the United Kingdom. The vaccine, known as mRNA-1018, is designed to combat a new strain of the influenza virus that has significantly impacted bird populations and livestock globally, while also being responsible for hundreds of human fatalities. The trial aims to assess the vaccine's safety and immunogenicity in approximately 4,000 healthy adults aged 18 and older. This development highlights the potential of mRNA technology to revolutionize pandemic responses, building on the success of mRNA vaccines during the COVID-19 pandemic. The trial is particularly focused on recruiting participants from the poultry industry and individuals over 65, who are considered most at risk.

Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research

Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research

The Texas Biomedical Research Institute has announced the creation of a $2 million Tuberculosis Innovation and Technology Fund. This fund, supported by philanthropic investments, aims to accelerate research and development of new therapies and cures for tuberculosis (TB), the world's deadliest infectious disease. The fund will support the recruitment of top scientific talent and the acquisition of advanced research technologies, such as the Akoya Phenocycler system and the Emulate Orb and Zoe Culture module system. These tools will enhance the study of TB at a cellular level, facilitating the development of new vaccines and therapeutics. Texas Biomed's initiative is part of a broader effort to combat TB, which remains a significant health concern in Texas and globally.

Texas Biomed Launches Tuberculosis Innovation Fund to Boost Research and Treatment

Texas Biomed Launches Tuberculosis Innovation Fund to Boost Research and Treatment

Texas Biomedical Research Institute has announced the establishment of a $2 million Tuberculosis Innovation and Technology Fund. This initiative is supported by philanthropic investments aimed at accelerating research and development of new therapies and cures for tuberculosis (TB), the world's deadliest infectious disease. The fund will enhance the institute's ability to recruit top scientific talent and acquire advanced research technologies. These technologies will allow for more detailed studies of disease mechanisms and interactions, potentially leading to breakthroughs in TB prevention and treatment. Texas Biomed's efforts are part of a broader global initiative to combat TB, which remains a significant health concern, particularly in Texas, where TB cases have been rising.

Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research and Treatment

Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research and Treatment

Texas Biomedical Research Institute has announced the establishment of a $2 million Tuberculosis Innovation and Technology Fund. This initiative is supported by philanthropic investments aimed at accelerating research and development of therapies for tuberculosis (TB), the world's deadliest infectious disease. The fund will be used to recruit top scientific talent and acquire advanced research technologies, such as the Akoya Phenocycler system and the Emulate Orb and Zoe Culture module system. These tools will enhance the study of disease mechanisms and aid in the development of new treatments. Texas Biomed, which hosts a premier NIH-funded TB research center, aims to strengthen its capabilities and contribute to global efforts to combat TB, which remains a significant health concern in Texas.

King's College London Researchers Unveil Vibrio Bacteria Structure, Paving Way for New Therapies

King's College London Researchers Unveil Vibrio Bacteria Structure, Paving Way for New Therapies

Researchers at King's College London have mapped the structure of Vibrio bacteria in unprecedented detail, a breakthrough that could lead to new treatments for infections caused by these bacteria. The study, published in Nature Communications, highlights the potential for targeting the bacteria's flagellum, a microscopic 'propeller' essential for its movement and infection capability. Vibrio bacteria, responsible for diseases like cholera and vibriosis, are increasingly resistant to antibiotics, posing a significant global health threat. The research team, led by Dr. Julien Bergeron, used advanced cryo-electron microscopy to visualize the flagellum and its protective sheath at atomic resolution. This detailed understanding could lead to interventions that impair the bacteria's ability to cause infections without promoting antibiotic resistance.

College Student Dies After Contracting Meningococcal Disease Following Portugal Trip

College Student Dies After Contracting Meningococcal Disease Following Portugal Trip

Alexander 'Zander' Philogene, a 21-year-old Australian university student, died after contracting meningococcal disease following a trip to Portugal. Philogene, who was studying finance and chemical engineering, began experiencing symptoms such as dizziness, headaches, and shortness of breath while returning to Austria from Porto, Portugal. Despite being vaccinated, it is suspected that he contracted a newer, aggressive strain of the disease recently discovered in the U.K. Philogene suffered a cardiac arrest at an airport in Austria and was airlifted to a local hospital, where he was pronounced dead. His sudden death has left his family and friends devastated, and a GoFundMe has been set up to support his funeral costs.

Pancreatic Cancer Vaccine Shows Promising Long-Term Results in Clinical Trial

Pancreatic Cancer Vaccine Shows Promising Long-Term Results in Clinical Trial

A personalized mRNA vaccine for pancreatic cancer has shown promising results in a phase 1 clinical trial, with extended follow-up data presented at the American Association for Cancer Research meeting. The trial involved 16 patients, half of whom developed a strong immune response to the vaccine. These 'responders' had a significantly lower recurrence rate and higher survival rate compared to non-responders. The vaccine is tailored to each patient's tumor antigens, aiming to prevent recurrence by targeting cancer cells remaining after surgery. The study, led by Dr. Vinod Balachandran at Memorial Sloan Kettering Cancer Center, highlights the potential of personalized cancer vaccines, though further research is needed to confirm these findings.

WHO's Big Catch-Up Initiative Delivers Over 100 Million Childhood Vaccinations Amid COVID-19 Disruptions

WHO's Big Catch-Up Initiative Delivers Over 100 Million Childhood Vaccinations Amid COVID-19 Disruptions

The World Health Organization (WHO), in collaboration with Gavi, the Vaccine Alliance, and UNICEF, has successfully delivered over 100 million vaccine doses to approximately 18.3 million children across 36 countries through the Big Catch-Up initiative. Launched during World Immunization Week 2023, this effort aimed to address the decline in vaccination rates caused by the COVID-19 pandemic. The initiative targeted 'zero-dose children' who had not received any vaccines and those who had missed measles vaccinations. The program concluded in March 2026 and is on track to meet its goal of reaching 21 million children. Despite this success, WHO and its partners emphasize the need for sustainable routine immunization programs to prevent future outbreaks of vaccine-preventable diseases.

Moderna Begins Pivotal Trial for H5N1 Bird Flu Vaccine in US and UK

Moderna Begins Pivotal Trial for H5N1 Bird Flu Vaccine in US and UK

Moderna has initiated a large-scale phase 3 trial for its mRNA-based vaccine, mRNA-1018, targeting the H5N1 bird flu virus. This trial involves around 4,000 healthy adults in the US and UK, focusing on poultry industry workers and individuals over 65, who are at higher risk. The H5N1 strain has been a significant threat to bird populations globally and poses a potential pandemic risk to humans. The trial aims to assess the vaccine's safety and immunogenicity, with Moderna planning to combine results with data from its seasonal flu vaccine for regulatory filings. The Coalition for Epidemic Preparedness Innovations (CEPI) is supporting the project, emphasizing the importance of mRNA technology in pandemic preparedness.

CEPI and Pasteur Network Partner to Enhance Vaccine R and Outbreak Preparedness

CEPI and Pasteur Network Partner to Enhance Vaccine R and Outbreak Preparedness

The Coalition for Epidemic Preparedness Innovations (CEPI) and the Pasteur Network have signed a Memorandum of Understanding to expand collaboration on vaccine research and development, manufacturing, and outbreak preparedness. This partnership aims to enhance regional capacity in vaccine R&D, clinical trials, and biosafety, particularly in the Global South. The collaboration seeks to advance equitable vaccine access and improve global readiness for future public health emergencies by leveraging CEPI's expertise and the Pasteur Network's strengths in disease surveillance and research.

U.S. Military Ends Mandatory Flu Vaccine for Troops, Citing Medical Autonomy

U.S. Military Ends Mandatory Flu Vaccine for Troops, Citing Medical Autonomy

Defense Secretary Pete Hegseth announced that the U.S. military will no longer mandate the flu vaccine for all service members, emphasizing 'medical autonomy' and religious freedom. This decision allows service members the choice to receive the flu vaccine but removes the requirement, a shift from longstanding military vaccination policies. The directive permits military branches to request maintaining the mandate within 15 days. Historically, vaccination has been a critical component of military health protocols, dating back to the American Revolution. The decision follows the rescinding of the COVID-19 vaccine mandate, which had led to the discharge of over 8,400 troops for non-compliance. The Pentagon has since reinstated 153 service members who were separated under the COVID-19 mandate.